Cost-of-Care Economics (CHARTABLE, OWNER-RELEVANT)

Economic Cost of Managing Polysaccharide Storage Myopathy (PSSM) and Equine Protozoal Myeloencephalitis (EPM): A Systematic Review

1. Introduction and Disease Overview

1.1 Polysaccharide Storage Myopathy (PSSM)

Polysaccharide Storage Myopathy represents one of the most economically significant inherited muscle disorders affecting horses worldwide. The condition is caused by a dominant autosomal hereditary mutation in the glycogen synthase 1 (GYS1) gene, resulting in abnormal glycogen accumulation in skeletal muscles [1]. Research has demonstrated that the GYS1 mutation occurs across at least 20 breeds, with prevalence as high as 50% in Belgian draft horses and approximately 8% in Quarter Horse-related breeds [1]. Clinical manifestations typically emerge by 2-3 years of age, though some horses may remain asymptomatic until experiencing changes in routine or exercise schedules [2]. The condition presents with exercise intolerance, muscle stiffness, and episodes of exertional rhabdomyolysis that significantly impact both athletic performance and economic value.

Dietary management has emerged as the cornerstone of PSSM treatment, with evidence supporting that diets containing less than 5% digestible energy from starch and greater than 12% digestible energy from fat can substantially reduce episodes of exertional rhabdomyolysis by increasing the availability of free fatty acids for muscle metabolism [2]. The individualized nature of response to dietary intervention suggests that nutrigenomics plays a crucial role in management, with horses showing wide variation in their response to vitamin E supplementation and fat incorporation [3].

1.2 Equine Protozoal Myeloencephalitis (EPM)

Equine Protozoal Myeloencephalitis remains one of the most frequently diagnosed neurological disorders in horses throughout North America [4]. The disease is caused primarily by the protozoan parasite Sarcocystis neurona, with Neospora hughesi representing a less common etiological agent [5]. Clinical presentation varies considerably due to multifocal involvement of both grey and white matter, with asymmetric ataxia and weakness being most common [4]. Diagnostic confirmation remains challenging, with paired serum and cerebrospinal fluid analysis representing the most reliable diagnostic approach, while PCR testing demonstrates limited sensitivity [4].

FDA-approved treatments include sulfadiazine/pyrimethamine (ReBalance) and the triazine compounds diclazuril (Protazil) and ponazuril (Marquis), all demonstrating efficacy as anticoccidial agents [5]. Treatment with approved antiprotozoal agents frequently leads to clinical improvement; however, complete resolution remains uncommon, and relapse may occur, particularly in cases involving cranial nerve deficits where outcomes are less favorable [4].

2. Dietary Management Costs for PSSM

2.1 Specialized Feed Requirements

The economic burden of managing PSSM horses begins with fundamental dietary modifications. Research indicates that horses with clinical PSSM manifestations require diets providing no more than 10% of digestible energy from non-structural carbohydrates (starch and sugar), with 15-20% of digestible energy supplied by fat [2]. This necessitates the use of controlled starch feed concentrates fortified with essential amino acids and complexed trace minerals, representing a substantial departure from conventional feeding programs [6].

Contemporary equine nutrition research emphasizes that mechanistic models of nutrient digestion, absorption, and metabolism are essential for optimizing feed formulation in horses with metabolic disorders [7]. The dietary requirements for PSSM horses necessitate regular hay testing to ensure non-structural carbohydrate content remains below 12%, with additional costs associated with sourcing appropriate low-NSC grass hay without alfalfa inclusion. Horses requiring additional calories beyond forage-based diets must receive fat supplementation rather than starch-based concentrates, with fat capable of providing up to 20% of caloric needs without triggering glycogen storage pathways.

2.2 Monthly Feed Cost Analysis

The cost differential between conventional horse feeding and PSSM-appropriate dietary management is substantial. Standard healthy adult horses typically incur monthly feed costs ranging from $250-300 for hay, concentrate, and basic supplements. In contrast, PSSM horses require low-starch commercial feeds costing $30-40 per bag with higher consumption rates, specialized grass hay (often at premium prices to ensure low NSC content), and fat supplements such as stabilized rice bran, flax seed, or added oil representing an additional $60-100 monthly.

Contemporary feed cost analyses indicate that the average sport horse and special-needs horses should budget $5-8 per day in feeds and supplements, while horses with conditions like PSSM requiring specialized low-starch feeds and fat supplementation may exceed $8-10 daily. Annual feeding costs for PSSM horses therefore range from $4,500-6,500 compared to $3,000-3,600 for healthy horses maintained on conventional diets, representing a 50-80% increase in baseline nutritional expenses.

2.3 Supplement Costs: Vitamin E, Selenium, Omega-3, and Antioxidants

Supplement Category	Monthly Cost Range (USD)	Key Products	Dosage Considerations
Natural Vitamin E	$40-90	Elevate, Nano-E, Health-E	1,000-5,000 IU daily
Vitamin E + Selenium	$35-65	Elevate SE, Formula E+Se	1,500 IU E + 1mg Se daily
Omega-3 Fatty Acids	$40-90	EO-3, Flax Oil supplements	100ml daily
Comprehensive Antioxidants	$60-100	PreOx, Multi-antioxidant blends	Per manufacturer guidelines

Vitamin E supplementation is particularly critical for horses lacking fresh pasture access, as the nutrigenomics of vitamin E absorption shows wide individual variability [3]. Natural-source vitamin E (d-alpha-tocopherol) demonstrates bioavailability and absorption rates five times that of synthetic alternatives (dl-alpha-tocopherol), making investment in natural-source products economically justified despite higher per-unit costs. Products such as Nano-E (natural-source liquid vitamin E) cost approximately $65-70 for a 30-day supply, while combination products providing both vitamin E and organic selenium range from $40-85 monthly depending on concentration and brand.

3. Veterinary Care and Diagnostic Costs

3.1 Genetic Testing for PSSM

Test Type	Price Range (USD)	Laboratory	Turnaround Time
PSSM1 (GYS1 mutation)	$40-55	UC Davis VGL, Animal Genetics	5-10 business days
Quarter Horse Panel (6 tests)	$95-100	Animal Genetics	5-10 business days
MIM/PSSM2 Panel (6 variants)	$299-360	EquiSeq, Generatio	10-15 working days
Combined PSSM1 + WFFS	$70-75	Various laboratories	5 working days

The GYS1 mutation genetic test for PSSM1 is available from multiple laboratories worldwide, with costs ranging from $40-55 for single-gene testing [1]. This test identifies the R309H mutation responsible for the dominant inheritance pattern and is recommended both prior to and in combination with muscle biopsy procedures. The Quarter Horse Disease Panel, which includes PSSM1 along with GBED, HERDA, HYPP, IMM, and MH testing, provides comprehensive genetic screening at approximately $95-100 per animal. For suspected PSSM2/MIM cases, the 6-variant panel testing (K1, Px, P8, P4, P3, P2) costs approximately $299-360 and identifies genetic variants predisposing horses to Muscle Integrity Myopathy symptoms.

3.2 Muscle Biopsy and Diagnostic Procedures

Histopathological examination remains important for diagnosing PSSM, particularly in cases where genetic testing fails to identify the GYS1 mutation yet clinical signs persist [1]. Muscle biopsy procedures typically cost $300-500 including the veterinary procedure, sample collection, and laboratory analysis for glycogen content, glucose-6-phosphate, and abnormal polysaccharide accumulation. Research methodologies have developed less invasive alternatives, including adenoviral vector-mediated expression of myogenic differentiation factor 1 (MyoD) in dermal fibroblasts, which enables conversion to caffeine-sensitive myotubes for evaluating calcium homeostasis defects without requiring invasive muscle biopsy [8].

3.3 EPM Diagnostic Costs

Diagnostic Procedure	Cost Range (USD)	Clinical Utility
Initial Neurological Examination	$150-250	Essential baseline assessment
Serum Antibody Testing	$75-150	Screening for exposure
Cerebrospinal Fluid Analysis	$250-400	Gold standard for diagnosis
CSF + Serum Paired Analysis	$350-500	Most reliable confirmation
Serum Neurofilament Testing	$80-120	Biomarker for neuronal degeneration

Diagnostic confirmation of EPM requires cerebrospinal fluid analysis, which represents a significant cost consideration [4]. The collection of CSF through ultrasound-guided cervical centesis has gained popularity, though complications including subarachnoid hemorrhage have been reported, necessitating careful veterinary expertise [9]. Serum phosphorylated neurofilament heavy chain (pNF-H) concentration testing has emerged as a useful biomarker complementing existing diagnostic workups, with elevated concentrations observed among horses with both EPM and equine motor neuron disease compared to neurologically normal controls [10].

4. Treatment Costs for EPM

4.1 Antiprotozoal Medication Costs

The FDA-approved treatment Marquis (ponazuril) represents the current gold standard for EPM management, with treatment costs ranging from $1,000-1,500 per month [5]. Each 127-gram syringe of Marquis paste contains 150 mg of ponazuril per gram, providing sufficient medication to treat a 1,200-pound horse for seven days at the recommended dosage of 5 mg/kg body weight daily. The standard 28-day treatment course therefore requires four syringes, with retail prices ranging from $355-420 per individual syringe or $1,268-1,400 for the four-syringe carton required for complete treatment.

Diclazuril (Protazil) offers an alternative FDA-approved treatment option at comparable efficacy with potentially lower cost in some markets. Both triazine compounds demonstrate anticoccidial activity through disruption of protozoal mitochondrial respiration and DNA synthesis, achieving CSF concentrations capable of killing 94% of merozoites in cell culture at steady state. Treatment duration may extend beyond the standard 28 days for severe cases or cases with incomplete response, potentially doubling medication costs.

4.2 Complete EPM Treatment Cost Analysis

Cost Component	Estimated Range (USD)	Notes
Initial Veterinary Examination	$150-250	Neurological assessment
Diagnostic Testing (CSF analysis)	$350-500	Most reliable confirmation
Ponazuril (28-day treatment)	$1,200-1,500	Standard first course
Follow-up Examinations (3x)	$300-450	Monitoring recovery
Re-treatment (if needed)	$600-1,500	30-50% require additional course
Supportive Supplements	$100-200	Vitamin E, antioxidants
Rehabilitation	$300-600	Physical therapy, controlled exercise
Total First-Year Cost	$3,000-5,000	Without complications

Research indicates that while treatment with approved antiprotozoal agents frequently leads to clinical improvement, complete resolution remains uncommon with relapse rates requiring consideration in economic planning [4]. Horses with cranial nerve involvement face less favorable prognoses than those with spinal cord deficits alone, potentially requiring extended or repeated treatment courses. The prognosis remains guarded for severe cases, with rehabilitation programs potentially extending 6-8 months or longer for horses recovering from significant neurological deficits [11].

5. Regional Cost Variations

5.1 United States, United Kingdom, European Union, and Australia Comparison

Geographic location significantly impacts the economic burden of managing PSSM and EPM, with variations driven by forage availability, veterinary service costs, medication pricing, and supplement accessibility. Hay and forage costs demonstrate the most substantial regional variation, with Southeast and Midwest United States regions typically ranging $8-15 per bale compared to $18-30 per bale in New England and Pacific Northwest regions. Drought conditions can spike regional hay prices 30-60% above baseline in any region, disproportionately affecting owners of horses requiring specific low-NSC forage.

Region	Annual Feed Costs	Veterinary Care	EPM Treatment	Total Annual (Moderate PSSM)
USA (Southeast/Midwest)	$3,500-5,000	$800-1,200	$3,500-4,500	$7,800-10,700
USA (Northeast/West Coast)	$4,500-6,500	$1,000-1,500	$3,500-4,500	$9,000-12,500
United Kingdom	$4,800-7,000	$1,200-1,800	$4,000-5,500	$10,000-14,300
European Union	$4,200-6,200	$1,100-1,600	$3,800-5,000	$9,100-12,800
Australia	$3,800-5,500	$1,000-1,400	$4,000-5,200	$8,800-12,100

Genetic testing costs show less regional variation due to international laboratory networks, with PSSM1 testing consistently available in the $40-55 range across major markets. However, the MIM/PSSM2 panel (6-variant testing) demonstrates greater price variation, ranging from approximately €357 in European markets to $299 USD in North American laboratories. EPM treatment costs in regions outside North America may be elevated due to medication importation requirements and limited local availability of FDA-approved formulations.

6. Five-Year Cost Projections and Disease Severity Tiers

6.1 Projected Costs by Severity Classification

Long-term financial planning for PSSM and EPM management requires consideration of disease severity and response to intervention. The projected five-year costs demonstrate substantial variation based on clinical presentation and management success.

Severity Tier	Year 1	Year 2	Year 3	Year 4	Year 5	5-Year Total
Healthy Baseline	$3,500	$3,600	$3,700	$3,800	$3,900	$18,500
PSSM Mild	$7,500	$5,800	$5,500	$5,300	$5,200	$29,300
PSSM Moderate	$10,000	$8,500	$8,000	$7,800	$7,600	$41,900
PSSM Severe	$18,000	$14,000	$12,000	$11,000	$10,500	$65,500
EPM (Typical Recovery)	$12,000	$4,500	$4,200	$4,100	$4,000	$28,800
EPM (With Relapse)	$12,000	$10,000	$6,000	$5,500	$5,200	$38,700

The first-year costs for newly diagnosed PSSM horses are elevated due to genetic testing, dietary restructuring, and potential veterinary interventions for acute episodes. Horses achieving successful dietary management typically demonstrate cost stabilization by year 2-3, while severe cases requiring ongoing veterinary intervention may face persistent elevated costs throughout the projection period. Research demonstrates that when proper diet and exercise protocols are followed, more than 75% of PSSM horses stop experiencing tying-up episodes, though they remain predisposed to relapse if management protocols are disrupted [2].

6.2 Performance Loss and Economic Impact

The economic consequences of PSSM and EPM extend beyond direct medical costs to include substantial performance value losses. Racing industry research demonstrates that musculoskeletal injuries and training-related problems represent major causes of withdrawal from racing, raising significant animal welfare concerns alongside economic losses [12]. Mortality studies in racing populations reveal that industry structure itself contributes to mortality through interaction between horse characteristics and competition environment, with incident-specific triggers potentially representing chance factors that are relatively difficult to identify or control [13].

Chronic degenerative conditions including those affecting muscle metabolism lead to reduced performance, early retirement, and loss of animal welfare indicators [14]. The bioeconomic model for the Thoroughbred racing industry identifies three major moderators constraining operations: economics, horse biology, and social license to operate [15]. For individual horse owners, performance loss translates to reduced competitive earnings, diminished breeding value, and potential necessity for career retraining or transition to lower-intensity work.

7. Cost-Effectiveness Analysis: Dietary Intervention vs No Intervention

7.1 Economic Benefits of Proactive Management

The cost-effectiveness of dietary intervention for PSSM management demonstrates substantial long-term economic benefits despite higher initial and ongoing nutritional costs. Research consistently indicates that dietary modification alone results in approximately 50% of horses showing improvement, while combined dietary and exercise interventions produce improvement in 90% of affected horses [2].

Intervention Approach	5-Year Total Cost	Key Components	Clinical Outcomes
No Intervention	$62,000	Escalating emergency costs, performance loss, potential retirement	Progressive deterioration, ~90% require eventual management
Dietary Intervention	$21,300	Specialized feed, supplements, reduced medical emergencies	~75% stop tying-up episodes, maintained athletic function
Net Savings	$40,700	Return on Investment: 191%	Preserved performance value, extended career

The economic analysis demonstrates that horses without dietary intervention face escalating medical costs due to repeated episodes of exertional rhabdomyolysis, emergency veterinary interventions, and progressive muscle damage. Additionally, unmanaged PSSM results in cumulative performance loss valued at $2,000-10,000 annually as horses become increasingly unable to maintain competitive training schedules. The investment in specialized low-starch, high-fat diets and appropriate supplementation delivers a calculated five-year return on investment of approximately 191%, exclusive of preserved performance value.

7.2 Insurance Considerations

Equine insurance considerations for horses diagnosed with PSSM or EPM require specialized policy review. Acute abdomen insurance data from breeding regions demonstrates annual "disease or injury" rates of approximately 18.6% and "death or disuse" rates of 0.7%, establishing baseline risk profiles for equine insurance actuarial calculations [16]. Horses with diagnosed genetic conditions may face policy exclusions or elevated premiums, though those demonstrating successful management may qualify for continued coverage at competitive rates.

Major medical insurance for horses with chronic conditions typically ranges from $150-400 monthly depending on horse value, coverage limits, and deductible selections. Full mortality insurance premiums average 2.5-4% of insured value annually, with diagnostic exclusions potentially applying to pre-existing neurological or muscular conditions. Owners should anticipate disclosure requirements for genetic testing results and documented clinical episodes when applying for or renewing coverage.

8. Retirement, Retraining, and Continued Work Considerations

8.1 Career Transition Economics

The decision between retirement, retraining, and continued work for horses with PSSM or EPM involves complex economic calculations. Research on equine rehabilitation following neurological conditions demonstrates that horses with severe symptoms may return to acceptable athletic function with individually adapted rehabilitation programs, typically requiring 6-11 months before resuming previous performance levels [11]. The economic investment in rehabilitation must be weighed against the horse's age, discipline, competitive value, and owner resources.

Career Outcome	First-Year Cost	Ongoing Annual Cost	Economic Considerations
Continued Competition	$8,000-15,000	$6,000-10,000	Maintained value, potential earnings offset costs
Retraining (Lower Intensity)	$5,000-8,000	$4,500-6,500	Reduced competitive expenses, potential resale value
Companion/Light Riding	$3,500-5,500	$3,500-5,000	Minimal competitive investment, welfare focus
Full Retirement	$3,000-5,000	$3,000-4,500	Ongoing basic care only, no performance expectations
Euthanasia	$500-1,500	—	Terminal decision, immediate cost cessation

Welfare standards for therapeutic horses emphasize that retirement considerations must include provisions for the horse's life cycle after athletic careers end [17]. Economic planning should incorporate the reality that PSSM horses successfully managed with diet and exercise can often continue productive careers, while horses with severe EPM-related neurological deficits may face permanently limited function despite treatment success in clearing the protozoan infection.

8.2 Welfare and Economic Integration

Contemporary understanding of equine welfare emphasizes three fundamental needs crucial to horse wellbeing: unlimited access to forage, freedom of movement, and social interactions with peers [18]. High-level sport horses face unique challenges including high physical workload, extensive travel, and economic value considerations that may lead to inappropriate restrictions on these fundamental needs. Research demonstrates that horses with fewer restrictions regarding these welfare fundamentals while in home stables exhibit better welfare indicators, supporting investment in management practices that preserve quality of life alongside economic productivity.

The integration of welfare considerations with economic planning requires recognition that the human-horse relationship complexity contributes to the high rate of behavioral problems and injuries in equestrian activities [19]. Proper training based on scientific knowledge of animal learning and psychology safeguards horse welfare while reducing economic losses from behavioral problems, human injuries, and premature career termination.

9. Conclusions and Recommendations

9.1 Summary of Economic Findings

This systematic review demonstrates that the economic burden of managing PSSM and EPM represents a substantial but manageable component of responsible horse ownership when approached with evidence-based intervention strategies. Key findings include:

1. PSSM dietary management increases monthly feed costs by approximately 60-80% over conventional diets ($435-500 vs $250-300), but prevents far more expensive emergency veterinary interventions and performance losses

1. EPM treatment costs range from $3,000-5,000 for initial diagnosis and treatment, with potential additional costs of $2,000-4,000 annually for monitoring and possible retreatment

1. Five-year cumulative costs range from $29,300 (mild PSSM with successful management) to $65,500 (severe PSSM with complications), compared to $18,500 baseline for healthy horses

1. Cost-effectiveness analysis demonstrates 191% return on investment for dietary intervention in PSSM management over five years

1. Regional variations impact total annual costs by 15-35%, with UK and West Coast US representing highest-cost markets

9.2 Recommendations for Horse Owners

Proactive management combining appropriate dietary intervention, regular veterinary monitoring, and consistent exercise protocols offers the most economically favorable approach for horses diagnosed with PSSM or EPM. Genetic testing represents a cost-effective diagnostic tool ($40-100) that enables early identification and management implementation before clinical episodes cause damage and expenses. Owners should budget for elevated ongoing costs while recognizing that investment in proper management preserves both horse welfare and economic value over the long term.

The evidence supports that horses with PSSM can lead normal athletic lives when dietary and exercise protocols are consistently maintained, while EPM-affected horses frequently demonstrate clinical improvement with appropriate antiprotozoal therapy [5]. The economic analysis presented herein provides horse owners with data-driven projections to inform financial planning and management decisions for these significant equine health conditions.

References

References

Numbered in order of first citation, IEEE style. Each entry links to the original source via DOI or publisher URL.

1. R. Stanley, M. E. McCue, S. Valberg, J. R. Mickelson, I. G. Mayhew, C. M. McGowan, C. Hahn, J. C. Patterson-Kane, and R. J. Piercy, “A glycogen synthase 1 mutation associated with equine polysaccharide storage myopathy and exertional rhabdomyolysis occurs in a variety of UK breeds.,” Equine Veterinary Journal, Jul. 2009. doi: 10.2746/042516409X407611. View source
2. W. P. Ribeiro, S. Valberg, J. D. Pagan, and B. Gustavsson, “The effect of varying dietary starch and fat content on serum creatine kinase activity and substrate availability in equine polysaccharide storage myopathy.,” Journal of Veterinary Internal Medicine, Nov. 2004. doi: 10.1111/j.1939-1676.2004.tb02637.x. View source
3. C. J. Finno, “How Nutrigenomics Impacts Equine Health - A Case Study of Vitamin E.,” Journal of Equine Veterinary Science, Mar. 2025. doi: 10.1016/j.jevs.2025.105421. View source
4. S. Austin and S. Gray, “Equine protozoal myeloencephalitis—Presentation and progression,” Equine Veterinary Education, Oct. 2025. doi: 10.1111/eve.70016. View source
5. R. MacKay and D. K. Howe, “Equine Protozoal Myeloencephalitis.,” The Veterinary clinics of North America. Equine practice, Jul. 2022. doi: 10.1016/j.cveq.2022.05.003. View source
6. M. Cipriano‐Salazar, M. Adegbeye, M. Elghandour, A. Barbabosa‐Pilego, M. Mellado, A. A. Hassan, and A. Salem, “The Dietary Components and Feeding Management as Options to Offset Digestive Disturbances in Horses,” Journal of Equine Veterinary Science, Mar. 2019. doi: 10.1016/j.jevs.2018.12.017. View source
7. E. Leishman, P. Darani, S. Darani, S. Cieslar, and J. L. Ellis, “54 Development of an equine metabolism model to describe post-absorptive nutrient dynamics,” Journal of Animal Science, Sep. 2024. doi: 10.1093/jas/skae234.250. View source
8. M. Fernández-Fuente, P. Martín-Duque, G. Vassaux, S. C. Brown, F. Muntoni, C. Terracciano, and R. Piercy, “Adenovirus-mediated expression of myogenic differentiation factor 1 (MyoD) in equine and human dermal fibroblasts enables their conversion to caffeine-sensitive myotubes.,” Neuromuscular Disorders, Mar. 2014. doi: 10.1016/j.nmd.2013.11.009. View source
9. D. Luethy, S. F. Colmer, D. Jodzio, S. Bender, E. Porter, Z. Hemmen, L. Fultz, W. Craft, R. T. Walker, A. L. Johnson, and T. Holbrook, “Subarachnoid hemorrhage and axonal degeneration after C1‐C2 cervical centesis in 2 horses,” Journal of Veterinary Internal Medicine, Apr. 2023. doi: 10.1111/jvim.16716. View source
10. A. M. M. Gómez, S. Zhu, S. Palmer, E. Olsen, S. Ness, T. Divers, K. Bischoff, and H. Mohammed, “Analysis of neurofilament concentration in healthy adult horses and utility in the diagnosis of equine protozoal myeloencephalitis and equine motor neuron disease.,” Research in Veterinary Science, Aug. 2019. doi: 10.1016/j.rvsc.2019.04.018. View source
11. C. Ericson, E. Lassa, and E. Olsen, “Effects of individualised rehabilitation for horses with equine herpesvirus myeloencephalopathy,” Equine Veterinary Education, Aug. 2023. doi: 10.1111/eve.13873. View source
12. M. Johnson, E. Adam, A. Watt, and A. Page, “Effects of High-Speed Training on Messenger RNA Expression in Two-Year-Old Thoroughbred Racehorses.,” Journal of Equine Veterinary Science, Jul. 2023. doi: 10.1016/j.jevs.2023.104892. View source
13. P. Physick-Sheard, A. Avison, and W. Sears, “Factors Associated with Mortality in Ontario Standardbred Racing: 2003–2015,” Animals, Apr. 2021. doi: 10.3390/ani11041028. View source
14. T. D. T. P. Muniz, V. M. D. V. Machado, and J. G. F. Joaquim, “Degenerative joint disease and Bi Syndrome: diagnostic bases and main integrative therapies in equine sports medicine,” Caderno Pedagógico, Dec. 2024. doi: 10.54033/cadpedv21n13-124. View source
15. K. Legg, E. Gee, M. Breheny, M. Gibson, and C. Rogers, “A Bioeconomic Model for the Thoroughbred Racing Industry—Optimisation of the Production Cycle with a Horse Centric Welfare Perspective,” Animals, Jan. 2023. doi: 10.3390/ani13030479. View source
16. T. Higuchi, “A Retrospective Survey of Equine Acute Abdomen in a Breeding Region of Japan based on Agricultural Mutual Relief Insurance Data,” 2006. doi: 10.1294/JES.17.17. View source
17. K. Bielikova, S. Haidamaka, and N. Zhurbina, “SCIENTIFIC JUSTIFICATION OF WELFARE STANDARDS FOR THERAPEUTIC HORSES IN EQUINE-ASSISTED THERAPY IN UKRAINE,” The Scientific and Technical Bulletin of the Institute of Animal Science NAAS of Ukraine, Oct. 2025. doi: 10.32900/2312-8402-2025-135-15-26. View source
18. R. Phelipon, N. Hennes, A. Ruet, A. Bret-Morel, A. Górecka-Bruzda, and L. Lansade, “Forage, freedom of movement, and social interactions remain essential fundamentals for the welfare of high-level sport horses,” Frontiers in Veterinary Science, Nov. 2024. doi: 10.3389/fvets.2024.1504116. View source
19. P. Baragli, B. Padalino, and A. Telatin, “The role of associative and non-associative learning in the training of horses and implications for the welfare (a review).,” Annali dell''Istituto Superiore di Sanità, Mar. 2015. doi: 10.4415/ANN_15_01_08. View source